Japan Tissue Engineering Co (TSE:7774) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
61 GF Score
Price 円612.00
GF Value 円517.75
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co FFO per Share?

FFO per Share only applies to REITs.

TSE:7774
61GF Score
Japan Tissue Engineering Co Ltd TSE:7774
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円612.00 is trading 18.2% above its estimated GF Value™ of 円517.75. GuruFocus considers Japan Tissue Engineering Co to be Modestly Overvalued.

Key valuation signals for TSE:7774:

  • FFO per Share:
  • GF Value™: 円517.75 vs. price of 円612.00 (18.2% above fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
61GF Score

Get the complete analysis for TSE:7774

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円612.00
Price
円517.75
GF Value